Neuroprotexeon Limited – Trademark Portfolio

Entity Type: 03

Neuroprotexeon Limited holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include XENEX. The owner is based in London.

52 Princes Gate, Exhibition Road

London SW72PG , GB

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

XENEX
XENEX
Registered 2016
XDS
XDS
Abandoned 2016

Trademark Classifications

Neuroprotexeon Limited's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Neuroprotexeon Limited have?

Neuroprotexeon Limited has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned.

What trademark classes does Neuroprotexeon Limited file in?

Neuroprotexeon Limited files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Neuroprotexeon Limited's most well-known trademarks?

Neuroprotexeon Limited's registered trademark portfolio includes well-known marks such as XENEX. These are among 1 currently registered trademark in the portfolio.

What is Neuroprotexeon Limited's trademark registration success rate?

Neuroprotexeon Limited has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.